ciglitazone has been researched along with Innate Inflammatory Response in 17 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae." | 7.75 | The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. ( de Vos, AF; Florquin, S; Stegenga, ME; van der Poll, T, 2009) |
| " Treatment with ciglitazone, which inhibits platelet CD40L expression, had no effect on pulmonary and systemic inflammation compared to controls." | 3.77 | Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. ( Boon, L; Gerards, MC; Jongsma, G; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2011) |
| " Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae." | 3.75 | The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. ( de Vos, AF; Florquin, S; Stegenga, ME; van der Poll, T, 2009) |
| " Ciglitazone inhibits the inflammation of HGBECs in vitro and has potential therapeutic effect on cholecystitis in vivo." | 3.73 | Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells. ( Cheng, NS; Li, SF; Liu, JW; Pan, GD; Wu, H; Xiong, XZ; Yan, LN; Zhang, GF, 2005) |
| " Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules." | 3.73 | Rosiglitazone ameliorates cisplatin-induced renal injury in mice. ( Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ, 2006) |
| " pylori lipopolysaccharide(LPS)-induced gastritis to assess the effect of a specific PPAR-gamma ligand, ciglitazone, on the apoptotic processes and the mucosal activity of inducible nitric oxide synthase (NOS-2), and the expression of COX-1 and -2 cyclooxygenases." | 3.71 | Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation. ( Slomiany, A; Slomiany, BL, 2002) |
| "Treatment with ciglitazone or 15d-PGJ2 reduced myocardial damage and neutrophil infiltration and blunted creatine kinase levels and cytokine production." | 1.34 | Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt. ( Burroughs, TJ; Denenberg, A; Hake, PW; Mangeshkar, P; O'Connor, M; Piraino, G; Wong, HR; Zingarelli, B, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, K | 1 |
| Li, Y | 1 |
| Yang, K | 1 |
| Gong, JP | 1 |
| Li, PZ | 1 |
| Stegenga, ME | 1 |
| Florquin, S | 1 |
| de Vos, AF | 1 |
| van der Poll, T | 1 |
| Tuinman, PR | 1 |
| Gerards, MC | 1 |
| Jongsma, G | 1 |
| Vlaar, AP | 1 |
| Boon, L | 1 |
| Juffermans, NP | 1 |
| Jun, HJ | 1 |
| Lim, HW | 1 |
| Choi, J | 1 |
| Jung, HH | 1 |
| Chae, SW | 1 |
| Syrovets, T | 1 |
| Schüle, A | 1 |
| Jendrach, M | 1 |
| Büchele, B | 1 |
| Simmet, T | 1 |
| Hinz, B | 1 |
| Brune, K | 1 |
| Pahl, A | 1 |
| Slomiany, BL | 1 |
| Slomiany, A | 1 |
| Woerly, G | 1 |
| Honda, K | 1 |
| Loyens, M | 1 |
| Papin, JP | 1 |
| Auwerx, J | 1 |
| Staels, B | 1 |
| Capron, M | 1 |
| Dombrowicz, D | 1 |
| Hammad, H | 1 |
| de Heer, HJ | 1 |
| Soullié, T | 1 |
| Angeli, V | 1 |
| Trottein, F | 1 |
| Hoogsteden, HC | 1 |
| Lambrecht, BN | 1 |
| Pan, GD | 1 |
| Wu, H | 1 |
| Liu, JW | 1 |
| Cheng, NS | 1 |
| Xiong, XZ | 1 |
| Li, SF | 1 |
| Zhang, GF | 1 |
| Yan, LN | 1 |
| Lee, S | 1 |
| Kim, W | 1 |
| Moon, SO | 1 |
| Sung, MJ | 1 |
| Kim, DH | 1 |
| Kang, KP | 1 |
| Jang, YB | 1 |
| Lee, JE | 1 |
| Jang, KY | 1 |
| Park, SK | 1 |
| Raikwar, HP | 1 |
| Muthian, G | 1 |
| Rajasingh, J | 1 |
| Johnson, CN | 1 |
| Bright, JJ | 1 |
| Zingarelli, B | 1 |
| Hake, PW | 1 |
| Mangeshkar, P | 1 |
| O'Connor, M | 1 |
| Burroughs, TJ | 1 |
| Piraino, G | 1 |
| Denenberg, A | 1 |
| Wong, HR | 1 |
| Kim, WJ | 1 |
| Kim, JH | 1 |
| Jang, SK | 1 |
| Kielian, T | 1 |
| Syed, MM | 1 |
| Liu, S | 1 |
| Phulwani, NK | 1 |
| Phillips, N | 1 |
| Wagoner, G | 1 |
| Drew, PD | 1 |
| Esen, N | 1 |
| Fitch, MT | 1 |
| Doller, C | 1 |
| Combs, CK | 1 |
| Landreth, GE | 1 |
| Silver, J | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
1 review available for ciglitazone and Innate Inflammatory Response
| Article | Year |
|---|---|
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
16 other studies available for ciglitazone and Innate Inflammatory Response
| Article | Year |
|---|---|
Effect of peroxisome proliferator-activated receptor γ on the cholesterol efflux of peritoneal macrophages in inflammation.
Topics: Animals; Cells, Cultured; Cholesterol; Hypoglycemic Agents; I-kappa B Proteins; Immunohistochemistry | 2014 |
The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice.
Topics: Animals; Colony Count, Microbial; Cytokines; Female; Hypoglycemic Agents; Inflammation; Lung; Mice; | 2009 |
Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury.
Topics: Acute Lung Injury; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Blood Platelets; Bronch | 2011 |
Ciglitazone inhibits cigarette smoke solution-induced inflammatory responses in human middle ear epithelial cells.
Topics: Blotting, Western; Cells, Cultured; Cytokines; Ear, Middle; Epithelial Cells; Humans; Inflammation; | 2012 |
Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity.
Topics: Chemotaxis, Leukocyte; Fibrinolysin; Humans; Inflammation; Interleukin-1; Mitogen-Activated Protein | 2002 |
15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism.
Topics: Cyclooxygenase 2; Gene Expression; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunol | 2003 |
Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation.
Topics: Animals; Apoptosis; Cyclooxygenase 2; Gastric Mucosa; Gastritis; Helicobacter pylori; Inflammation; | 2002 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation | 2003 |
Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma.
Topics: Anilides; Animals; Asthma; Cell Movement; Cytokines; Dendritic Cells; Disease Models, Animal; Eosino | 2004 |
Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells.
Topics: Cells, Cultured; Cholecystitis; Epidermal Growth Factor; Epithelial Cells; Gallbladder; Humans; Infl | 2005 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinica | 2006 |
PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2.
Topics: Animals; Antigens; Benzamides; Benzhydryl Compounds; Cell Differentiation; Cell Proliferation; Demye | 2006 |
Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.
Topics: Anilides; Animals; Creatine Kinase; DNA-Binding Proteins; Heat Shock Transcription Factors; HSP70 He | 2007 |
Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arsenites; Chromans; Cyclopentanes; Cytoplasmic Granules | 2007 |
The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses.
Topics: Animals; Brain Abscess; Cell Wall; Fibronectins; Inflammation; Ligands; Macrophages; Mice; Mice, Inb | 2008 |
Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma.
Topics: Animals; Animals, Newborn; Astrocytes; Axons; Brain Injuries; Cell Movement; Cells, Cultured; Cerebr | 1999 |